AMT could stop ulceration

Article

Amniotic membrane transplantation (AMT) may stop corneal ulceration and promote epithelialization, according to an investigation.

Amniotic membrane transplantation (AMT) may stop corneal ulceration and promote epithelialization, according to an investigation.

Dr Stanislav A. Iakimenko et al., Department of Eye Burns, Ophthalmic Plastic Surgery, Keratoplasty and Keratoprosthesis, State Institution,The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Ukraine, analysed the results of 55 AMTs in 53 eyes of 53 patients.

All patients had corneal ulceration and limbal deficiency 180-360° of the limbus after grade 4-6 chemical and thermal injuries was performed. The preoperative visual acuity (VA) was

The findings showed that corneal ulceration was prevented in 98.1% of cases and corneas were epithelialized in 76.3% of AMTs. Corneal defect recurred in 7.1% of successful cases and VA was ≥0.01 in 54.8% of patients after corneal epithelialization.

VA at the last follow-up visit improved on 2 or more lines on the eye chart, compared to preoperative VA in 35.7% with corneal epithelialization. VA didn’t improve in 42.9% of successful patients and it reduced by one line in 26.2% of patients.

Please visit the latest online issue of the European Journal of Ophthalmology to see the abstract.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.